Company intelligence / Profile preview

Rare Thyroid Therapeutics International

Stockholm, Stockholm County, Swedenrarethyroid.com ↗

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Rare Thyroid Therapeutics (RTT) is a Swedish biopharmaceutical company focused on developing therapies for rare thyroid hormone signaling disorders. The company's lead asset is Emcitate (tiratricol), a small-molecule thyroid hormone receptor agonist developed to treat monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome. In November 2020, RTT was acquired by PledPharma, which subsequently rebranded as Egetis Therapeutics. Following regulatory approvals in Europe in 2025 and the United States in 2026, Emcitate became the first approved therapy for MCT8 deficiency.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

Erasmus Medical CenterEr-Kim

Beyond the preview

Go deeper on Rare Thyroid Therapeutics International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rare Thyroid Therapeutics International.